Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 3

1.

Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET Inhibition.

Bachleitner-Hofmann T, Sun MY, Chen CT, Liska D, Zeng Z, Viale A, Olshen AB, Mittlboeck M, Christensen JG, Rosen N, Solit DB, Weiser MR.

Clin Cancer Res. 2011 Jan 1;17(1):122-33. doi: 10.1158/1078-0432.CCR-10-0253.

2.

Recent Advances in the Design and Synthesis of c-Met Inhibitors as Anticancer Agents (2014-Present).

Lv PC, Wang ZC, Zhu HL.

Curr Med Chem. 2017;24(1):57-64. doi: 10.2174/0929867323666161028161441. Review.

PMID:
27804876
3.

The Met tyrosine kinase receptor as a therapeutic target and a potential cancer stem cell factor responsible for therapy resistance (Review).

Miekus K.

Oncol Rep. 2017 Feb;37(2):647-656. doi: 10.3892/or.2016.5297. Epub 2016 Dec 7. Review.

PMID:
27959446

Supplemental Content

Support Center